## #2605 store at -20C

## Phospho-PAK1 (Ser199/204)/PAK2 (Ser192/197) Antibody



Orders:877-616-CELL (2355)<br/>orders@cellsignal.comSupport:877-678-TECH (8324)Web:info@cellsignal.com<br/>cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W	<b>Reactivity:</b> H M R GP	<b>Sensitivity:</b> Endogenous	<b>MW (kDa):</b> 61 to 67 (PAK2), 68 to 74 (PAK1/3)	<b>Source/Isotype:</b> Rabbit	<b>UniProt ID:</b> #Q13153, #Q13177	<b>Entrez-Gene Id:</b> 5058, 5062
Product Usage Information	9	<b>Application</b> Western Blotting			Dilution 1:1000	
Storage		Supplied in 10 mM s 20°C. Do not aliquot		150 mM NaCl, 100 μ	g/ml BSA and 50% glyc	erol. Store at –
Specificity/Sensitivity		Phospho-PAK1 (Ser199/204)/PAK2 (Ser192/197) Antibody detects endogenous levels of Ser199/204 phosphorylated PAK1 or Ser192/197 phosphorylated PAK2. It may also detect Ser200/205 phosphorylated PAK3, however it does not cross-react with phosphorylated PAK4.				
Source / Purification		Polyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding serine 199/204 of human PAK1. Antibodies are purified by protein A and peptide affinity chromatography.				
Background		processes, including phagocyte NADPH o that induce PAK activ the amino terminus Phosphorylation of F sites have been iden Because the autopho been hypothesized t conformation (6). Re in the kinase inhibito PAK2 regulates bind similarity with PAK1- site analogous to Th	cytoskeletal reorganiz xidase, and growth fac vity have been reporte of PAK causes autopho PAK1 at Thr423 by PDK tified, including Ser19 osphorylation sites are hat modification in thi search indicates that p ory domain) affects kin ing with the adaptor p 3 in the amino-termina r423 of PAK1, may play	ation, MAPK signalin tor-induced neurite d. Binding of Rac/Cdo psphorylation and co induces activation o and Ser204 of PAK1 located in the amino s region prevents the hosphorylation at Se ase activity (7). Phos rotein Nck (8). PAK4, al regulatory region ( v a pivotal role in reg	es is engaged in multip og, apoptotic signaling, outgrowth (1,2). Severa c42 to the CRIB (or PBD nformational changes f PAK1 (3). Several auto l, and Ser192 and Ser19 o-terminal inhibitory do e kinase from reverting er144 of PAK1 or Ser139 ohorylation at Ser21 of PAK5/7, and PAK6 have 9). Phosphorylation at ulating the activity and expressed in human ca	control of Il mechanisms I) domain near in PAK (1). phosphorylation 07 of PAK2 (4,5). omain, it has to an inactive 0 of PAK3 (located PAK1 or Ser20 of e lower sequence Ser474 of PAK4, a function of PAK4
Background R	eferences	2. Daniels, R.H. et al. 3. King, C.C. et al. (20 4. Manser, E. et al. (19 5. Gatti, A. et al. (199 6. Lei, M. et al. (2000 7. Chong, C. et al. (200 9. Abo, A. et al. (1998 10. Qu, J. et al. (2001 11. Wen, Y.Y. et al. (2)	okoch, G.M. (1998) <i>Int.</i> (1998) <i>EMBO J.</i> 17, 75- (1998) <i>EMBO J.</i> 17, 75- (1997) <i>Mol. Cell. Biol.</i> 17, (19) <i>J. Biol. Chem.</i> 274, 8 (10) <i>J. Biol. Chem.</i> 274, 8 (10) <i>Mol. Cell. Biol.</i> 20, 3 (11) <i>J. Biol. Chem.</i> 276, (11) <i>J. Biol. Chem.</i> 276, (12) <i>Mol. Cell. Biol.</i> 20, 3 (13) <i>EMBO J.</i> 17, 6527-40. (14) <i>Expert Opin Ther</i> (2009) <i>Oncogene</i> 28, 25	4-64. 41201-9. 1129-43. 022-8. 17347-53. 906-17. 23-33. <i>Targets</i> 18, 807-15.	. 30, 857-62.	
Species Reacti	vity	Species reactivity is o	determined by testing	in at least one appro	ved application (e.g., w	estern blot).
Western Blot Buffer		IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.				
Applications Key		W: Western Blotting				
Cross-Reactivity Key		H: Human M: Mouse R: Rat GP: Guinea Pig				

Trademarks and Patents	Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.		
	All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.		
Limited Uses	Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.		
	Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.		